NCT00535132 - Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Schizophrenia

Interventions

DRUG

Oral Risperidone

4 or 6 mg MG once daily for 0-2 weeks

DRUG

Paliperidone ER

6, 9 or 12 MG once daily for 4-6 weeks

Trial Locations (40)

Unknown

Cerritos

Garden Grove

Huntington Beach

Pico Rivera

San Diego

Santa Ana

Torrance

Atlanta

Chicago

Flowood

Clementon

Brooklyn

Philadelphia

Austin

Irving

Miami

Buenos Aires

Ciudad Autonoma de

Cordoba Crd

Mendoza

Mendoza Men

Rosario

Barranquilla

Bogotá

Bogotá S/N

Bucaramanga S/N

Pilsen

Prague

Sternberk

Bojnice

Bratislava

Michalovce

Rimavská Sobota

Žilina

Dnipropetrovsk

Donetsk

Kiev

Lviv

Odesa

Village Stepanovka Kherson

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY